A lawsuit was filed for certain investors in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares. Investors who purchased shares of Regeneron ...

At the heart of the controversy is Regeneron's alleged practice of paying credit card fees to distributors, on the condition that these fees were not passed on to Eylea customers. This arrangement, ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. While stocks initially fell based on worries regarding Trump ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best growth stocks to invest in according to analysts. Companies ...

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one ...

SAN FRANCISCO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is facing headwinds on multiple fronts, including disappointing sales figures, ongoing legal ...

Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various serious medical conditions.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...